NDT Advance Access published online on October 4, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfi113
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Nephrology and Clinical Immunology, C.H.U. Tours, Tours, France
* To whom correspondence should be addressed. Background. Therapeutic drug monitoring for cyclosporine microemulsion (CsA-ME) is often performed using either trough levels (C0) or levels at 2 h post-dose (C2). This analysis assessed changes in C0 and C2 and their relationship to CsA-ME dose over time post-transplant in renal transplant patients. Methods. Data were obtained from MO2ART, a prospective multicentre trial in which CsA-ME dose was adjusted based on C2 level. All 98 patients in whom C0 and C2 were available at day 5, month 3 and month 12 were included, out of 234 who completed the 12 month study. Normalized dose (ND) of CsA-ME, defined as dose per kilogram body weight, was calculated, together with C0/ND, C2/ND and C2/C0. Results. C0/ND and C2/ND both increased between day 5 and month 3: C0/ND from 33±15 to 53±24 (ng/ml)/(mg/kg) and C2/ND from 161±64 to 248±80 (ng/ml)/(mg/kg). Between month 3 and month 12, C2/ND remained stable but C0/ND decreased to 42±20 (ng/ml)/(mg/kg) while the C2/C0 ratio increased from 5.2±1.9 to 6.5±2.3, indicating an acceleration of drug elimination. The inter-individual coefficient of variation was higher for C0/ND than for C2/ND at 3 months (45 vs 32%, P<0.05) and at 12 months (48 vs 31%, P<0.01). Conclusions. CsA clearance accelerates between months 3 and 12 post-transplant, resulting in lower C0 levels for a given exposure (as measured by C2). As a consequence, C0 monitoring may progressively underestimate CsA exposure during the first year post-transplant. C2 monitoring contributes to improved individualized CsA-ME treatment in both the de novo phase and beyond month 3.
Received April 21, 2005
Accepted August 8, 2005
Original Articles
Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases
2 Royal Prince Alfred Hospital, Sydney, Australia
3 Renal Transplant Program, Toronto General Hospital, Toronto, Canada
4 Medical Department of Nephrology, Rikshospitalet, Oslo, Norway
5 Department of Renal Transplantation and Intensive Care, Hôpital Necker, Paris, France
6 Novartis Pharma AG, Basel, Switzerland
7 Department of Medicine, University of British Columbia, Vancouver, Canada
Matthias Büchler, E-mail: buchler{at}med.univ-tours.fr
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Sommerer, T. Giese, S. Meuer, and M. Zeier Pharmacodynamic monitoring of calcineurin inhibitor therapy: Is there a clinical benefit? Nephrol. Dial. Transplant., January 1, 2009; 24(1): 21 - 27. [Full Text] [PDF]
|
|